TITLE

Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques

AUTHOR(S)
Belyakov, Igor M.; Hel, Zdenek; Kelsall, Brian; Kuznetsov, Vladimir A.; Ahlers, Jeffrey D.; Nacsa, Janos; Watkins, David I.; Allen, Todd M.; Sette, Alessandro; Altman, John; Woodward, Ruth; Markham, Phillip D.; Clements, John D.; Franchini, Genoveffa; Strober, Warren; Berzofsky, Jay A.
PUB. DATE
December 2001
SOURCE
Nature Medicine;Dec2001, Vol. 7 Issue 12, p1320
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Given the mucosal transmission of HIV-1, we compared whether a mucosal vaccine could induce mucosal cytotoxic T lymphocytes (CTLs) and protect rhesus macaques against mucosal infection with simian/human immunodeficiency virus (SHIV) more effectively than the same vaccine given subcutaneously. Here we show that mucosal CTLs specific for simian immunodeficiency virus can be induced by intrarectal immunization of macaques with a synthetic-peptide vaccine incorporating the LT(R192G) adjuvant. This response correlated with the level of T-helper response. After intrarectal challenge with pathogenic SHIV-Ku2, viral titers were eliminated more completely (to undetectable levels) both in blood and intestine, a major reservoir for virus replication, in intrarectally immunized animals than in subcutaneously immunized or control macaques. Moreover, CD4+ T cells were better preserved. Thus, induction of CTLs in the intestinal mucosa, a key site of virus replication, with a mucosal AIDS vaccine ameliorates infection by SHIV in non-human primates.
ACCESSION #
9511198

 

Related Articles

  • Therapeutic DNA Vaccine Induces Broad T Cell Responses in the Gut and Sustained Protection from Viral Rebound and AIDS in SIV-Infected Rhesus Macaques. Fuller, Deborah Heydenburg; Rajakumar, Premeela; Che, Jenny W.; Narendran, Amithi; Nyaundi, Julia; Michael, Heather; Yager, Eric J.; Stagnar, Cristy; Wahlberg, Brendon; Taber, Rachel; Haynes, Joel R.; Cook, Fiona C.; Ertl, Peter; Tite, John; Amedee, Angela M.; Murphey-Corb, Michael // PLoS ONE;Mar2012, Vol. 7 Issue 3, p1 

    Immunotherapies that induce durable immune control of chronic HIV infection may eliminate the need for life-long dependence on drugs. We investigated a DNA vaccine formulated with a novel genetic adjuvant that stimulates immune responses in the blood and gut for the ability to improve therapy in...

  • Therapeutic DNA Vaccine Induces Broad T Cell Responses in the Gut and Sustained Protection from Viral Rebound and AIDS in SIV-Infected Rhesus Macaques. Fuller, Deborah Heydenburg; Rajakumar, Premeela; Che, Jenny W.; Narendran, Amithi; Nyaundi, Julia; Michael, Heather; Yager, Eric J.; Stagnar, Cristy; Wahlberg, Brendon; Taber, Rachel; Haynes, Joel R.; Cook, Fiona C.; Ertl, Peter; Tite, John; Amedee, Angela M.; Murphey-Corb, Michael // PLoS ONE;Mar2012, Vol. 7 Issue 3, p1 

    Immunotherapies that induce durable immune control of chronic HIV infection may eliminate the need for life-long dependence on drugs. We investigated a DNA vaccine formulated with a novel genetic adjuvant that stimulates immune responses in the blood and gut for the ability to improve therapy in...

  • Successful DNA immunization against measles: Neutralizing antibody against either the hemagglutinin or fusion glycoprotein protects rhesus macaques without evidence of atypical measles. Polack, Fernando P.; Lee, Sok H.; Permar, Sallie; Manyara, Elizabeth; Nousari, Hossein G.; Jeng, Yaikah; Mustafa, Farah; Valsamakis, Alexandra; Adams, Robert J.; Robinson, Harriet L.; Griffin, Diane E. // Nature Medicine;Jul2000, Vol. 6 Issue 7, p776 

    Measles remains a principal cause of worldwide mortality, in part because young infants cannot be immunized effectively. Development of new vaccines has been hindered by previous experience with a formalin-inactivated vaccine that predisposed to a severe form of disease (atypical measles). Here...

  • Depletion of CD4⁺ T cells abrogates post-peak decline of viremia in SIV-infected rhesus macaques. Ortiz, Alexandra M.; Klatt, Nichole R.; Bing Li; Yi, Yanjie; Tabb, Brian; Xing Pei Hao; Sternberg, Lawrence; Lawson, Benton; Carnathan, Paul M.; Cramer, Elizabeth M.; Engram, Jessica C.; Little, Dawn M.; Ryzhova, Elena; Gonzalez-Scarano, Francisco; Paiardini, Mirko; Ansari, Aftab A.; Ratcliffe, Sarah; Else, James G.; Brenchley, Jason M.; Collman, Ronald G. // Journal of Clinical Investigation;Nov2011, Vol. 121 Issue 11, p4433 

    CD4+ T cells play a central role in the immunopathogenesis of HIV/AIDS, and their depletion during chronic HIV infection is a hallmark of disease progression. However, the relative contribution of CD4+ T cells as mediators of antiviral immune responses and targets for virus replication is still...

  • Protective CD8+ T lymphocytes in Primates Immunized with Malaria Sporozoites. Weiss, Walter R.; Jiang, Chengyong George // PLoS ONE;Feb2012, Vol. 7 Issue 2, p1 

    Live attenuated malaria vaccines are more potent than the recombinant protein, bacterial or viral platform vaccines that have been tested, and an attenuated sporozoite vaccine against falciparum malaria is being developed for humans. In mice, attenuated malaria sporozoite vaccines induce CD8+...

  • Protective CD8+ T lymphocytes in Primates Immunized with Malaria Sporozoites. Weiss, Walter R.; Jiang, Chengyong George // PLoS ONE;Feb2012, Vol. 7 Issue 2, p1 

    Live attenuated malaria vaccines are more potent than the recombinant protein, bacterial or viral platform vaccines that have been tested, and an attenuated sporozoite vaccine against falciparum malaria is being developed for humans. In mice, attenuated malaria sporozoite vaccines induce CD8+...

  • SHIV Infection Protects Against Heterologous Pathogenic SHIV Challenge in Macaques: A Gold-Standard for HIV-1 Vaccine Development? Sealy, Robert; Xiaoyan Zhan; Lockey, Timothy D.; Martin, Louis; Blanchard, James; Traina-Dorge, Vicki; Hurwitz, Julia L. // Current HIV Research;Sep2009, Vol. 7 Issue 5, p497 

    A current debate in the HIV-1 vaccine field concerns the ability of an immunodeficiency virus to elicit a protective response. One argument is that HIV-1 superinfections are frequent in healthy individuals, because virus evades conventional immune surveillance, a serious obstacle to vaccine...

  • Comparison of Neutralizing Antibody Responses Elicited from Highly Diverse Polyvalent Heterotrimeric HIV-1 gp140 Cocktail Immunogens versus a Monovalent Counterpart in Rhesus Macaques. Bowles, Emma J.; Schiffner, Torben; Rosario, Maximillian; Needham, Gemma A.; Ramaswamy, Meghna; McGouran, Joanna; Kessler, Benedikt; LaBranche, Celia; McMichael, Andrew J.; Montefiori, David; Sattentau, Quentin J.; Hanke, Tomáš; Stewart-Jones, Guillaume B. E. // PLoS ONE;Dec2014, Vol. 9 Issue 12, p1 

    Eliciting neutralizing antibodies capable of inactivating a broad spectrum of HIV-1 strains is a major goal of HIV-1 vaccine design. The challenge is that envelopes (Envs) of circulating viruses are almost certainly different from any Env used in a vaccine. A novel immunogen composed of a highly...

  • rBCG Induces Strong Antigen-Specific T Cell Responses in Rhesus Macaques in a Prime-Boost Setting with an Adenovirus 35 Tuberculosis Vaccine Vector. Magalhaes, Isabelle; Sizemore, Donata R.; Ahmed, Raija K.; Mueller, Stefanie; Wehlin, Lena; Scanga, Charles; Weichold, Frank; Schirru, Giulia; Pau, Maria Grazia; Goudsmit, Jaap; Kühlmann-Berenzon, Sharon; Spångberg, Mats; Andersson, Jan; Gaines, Hans; Thorstensson, Rigmor; Skeiky, Yasir A. W.; Sadoff, Jerry; Maeurer, Markus // PLoS ONE;2008, Vol. 3 Issue 11, p1 

    Background: BCG vaccination, combined with adenoviral-delivered boosts, represents a reasonable strategy to augment, broaden and prolong immune protection against tuberculosis (TB). We tested BCG (SSI1331) (in 6 animals, delivered intradermally) and a recombinant (rBCG) AFRO-1 expressing...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics